BioSpace News Archive

CONMED Corporation (NYSE: CNMD) today announced that it will report financial results for the third quarter 2021 after the market close on October 27, 2021.

Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the ACON Laboratories Flowflex COVID-19 Home Test, an over-the-counter (OTC) COVID-19 antigen test, which adds to the growing list of tests that can be used at home without a prescription.

BD announced that it will report its fiscal 2021 fourth quarter and full year financial results on Thursday, Nov. 4, 2021.

Renovacor, Inc., a biotechnology company developing adeno-associated virus ‑based gene therapies for devastating cardiovascular and central nervous system diseases resulting from BAG3 gene variants, announced the appointment of Kumar Dhanasekharan, Ph.D., as Senior Vice President of Technical Operations.

Sierra Oncology, Inc., a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer, granted stock options to two new employees as approved by the Compensation Committee of the Company’s Board of Directors, under Sierra Oncology’s 2018 Equity Inducement Plan.

Asensus Surgical, Inc., a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, announced that Paul LaViolette, who has served as the Company’s Board Chair since 2013, will step down as Chair in late October, and intends to leave the Board before the end of the year.

Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that DEKRA Notified Body has approved the Company’s proposed indication for the Genio® system to treat patients with a Complete Concentric Collapse (“CCC”).

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced new clinical and preclinical research will be presented at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics, taking place October 7 - 10, 2021.

Exicure, Inc.® (NASDAQ: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) technology, today announced a presentation at the Chardan Virtual 5th Annual Genetic Medicines Conference on Tuesday, October 5, 2021.